Ken Griffin Graphite Bio, Inc. Transaction History

Citadel Advisors LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$2.24 - $2.66 $1.47 Million - $1.74 Million	-655,735 Reduced 52.78%	586,724 $1.54 Million
Q3 2023 Nov 14, 2023	BUY	$2.18 - $2.77 $83,197 - $105,714	38,164 Added 3.17%	1,242,459 $3.08 Million
Q2 2023 Aug 14, 2023	BUY	$2.47 - $3.38 $81,801 - $111,938	33,118 Added 2.83%	1,204,295 $3.13 Million
Q1 2023 May 15, 2023	SELL	$1.85 - $3.21 $35,590 - $61,753	-19,238 Reduced 1.62%	1,171,177 $2.87 Million
Q4 2022 Feb 14, 2023	SELL	$2.82 - $3.59 $235,842 - $300,238	-83,632 Reduced 6.56%	1,190,415 $3.95 Million
Q3 2022 Nov 14, 2022	SELL	$2.82 - $4.24 $129,124 - $194,145	-45,789 Reduced 3.47%	1,274,047 $4.04 Million

637K

Ticker GRPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,211,200
Description
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expres...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.